TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...

Novavax Inc.’s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected ...

Novavax shares fell after the company dropped its full-year revenue guidance with its third-quarter results. The company has ...

Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for ...

Novavax ends UK COVID-19 vaccine contract, agreeing to repay $123.8M in quarterly installments by 2027 as part of settlement. Vandana Singh Robinhood, Novavax, Phunware, Lucid Group, And Tesla ...

Shares of Novavax Inc. NVAX slid 6.10% to $8.46 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.09% to 19,281.40 ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Impact of the Clinical Hold on Novavax Stock This clinical hold is likely to delay Novavax’s original plans to start the phase III immunogenicity study on the CIC and standalone flu vaccines ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...